

Dominik Ellenrieder

Swiss (born 1958)

Vice Chairman of the Board of Directors since 2000

Chairman of the Remuneration Committee since 2017

Member of the Finance and Audit Committee since 2017

Dominik Ellenrieder joined Medartis in 2000 as shareholder and Vice Chairman of the Board.

Dominik Ellenrieder holds a degree in economics from the University of Basel and an MBA from GSBA (Graduate School of Business Administration Zurich) and Boston University.

He served as Manager Business Units and Sales Subsidiaries at Stratec Medical, the European subsidiary of Synthes-Stratec Inc. (later Johnson & Johnson), a world leader in the field of trauma, spine, maxillofacial and surgical powertools. Dominik Ellenrieder was part of the core team that developed Stratec Medical from the MBO in 1990 to the IPO in 1996 and to the merger with Synthes Inc. in 1999. Prior to that, Dominik Ellenrieder served as Head of International Sales at Protek AG (later Sulzer Medica, Zimmer), a company specializing in hip and knee joint medical technology. In 2000, Dominik Ellenrieder co-founded Kuros Therapeutics AG, where he served as Chairman until the trade sale in 2002. From 2003 to 2015, he acted as Vice Chairman at Kuros Biosciences AG. In addition, he has been a Board Member and Head of Technical Committee of Straumann Holding AG, a pioneer of dental implants and a global leader in tooth replacement, orthodontic solutions and restorative dentistry, from 2001 to 2014. Since 2006, Dominik Ellenrieder has been Chairman of the Board of Directors and the majority shareholder of Sentec AG, a company founded in 2000 that focuses on non-invasive continuous patient monitoring. He is Venture Partner at Endeavour Vision SA since 2007. From 2015 to early 2017, he served as Chairman of Symetis AG, the leading European company in minimally invasive heart valve replacement devices (TAVI) that was acquired by Boston Scientific in March 2017. Other mandates include QGel SA, NexMed Holding AG and Le Grand Hotel Chandolin SA:

Dominik Ellenrieder complements the Board with his expert know-how in the development and marketing of medical devices and his extensive and sound experience in building and managing medical technology companies as an executive and board member in both Europe and the USA.